Search

Displaying results 4341 - 4350 of 10000 in total
  1. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    It reduces appetite and increases satiety in obese patients.

  2. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

    Synonyms: G17DT (AN ANTIGASTRIN IMMUNOGEN)
  3. Drug

    AVI-4557

    go.drugbank.com/drugs/DB05447
    Experimental

    in clearance and an increase in maximal blood concentration (Cmax). … AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently

  4. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity … Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.

  5. Drug

    Cilazaprilat

    go.drugbank.com/drugs/DB15565
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    It is believed that similar effects would be seen in cells isolated from hypertrophic scars. … In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control.

  7. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.

  8. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

  9. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.

  10. Drug

    Omburtamab

    go.drugbank.com/drugs/DB15635
    Investigational

    [A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. … [A191829] Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).